Definition
Natriuretic peptides are a family of structurally related but genetically distinct hormones/paracrine factors that regulate blood volume, blood pressure, ventricular hypertrophy, pulmonary hypertension, fat metabolism, and long bone growth. The mammalian members are atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) 1.
Discovery
De Bold et al reported the first direct evidence of natriuretic substance in 19812. They found that the IV injection of atrial, but not ventricular, homogenates into rats elicited a rapid decrease in blood pressure that was accompanied by increased renal sodium and water excretion. After this seminal observation, several groups purified peptides of varying sizes from atrial tissue that possess both natriuretic and smooth muscle-relaxing activity. These peptides were given a number of different names such as ANP, cardionatrin, cardiodilatin, atriopeptin, and the first description is most often used today. BNP, which was originally called brain natriuretic peptide and CNP were subsequently purified from porcine brain extracts based on their ability to relax smooth muscle.
Structural Characteristics
The natriuretic peptides are a family of ring shaped vasoactive hormones showing considerable sequence homology. All three members contain the conserved sequence CFGXXXDRIXXXXGLGC where X is any amino acid. The flanking cysteines form a 17-amino-acid disulfide-linked ring that is required for biological activity. All natriuretic peptides are synthesized as preprohormones. Human preproANP is 151 amino acids in length. Cleavage of the amino terminal signal sequence results in the 126-amino-acid proANP, which is the predominant form stored in atrial granules. ProANP is rapidly cleaved upon secretion by the transmembrane cardiac serine protease called corin to form the biologically active carboxyl-terminal 28-amino-acid peptide. Human BNP is synthesized as a preprohormone of 134 residues containing a signal sequence that is cleaved to yield a 108-amino-acid prohormone. Additional cleavage by an unknown protease results in an inactive 76-residue amino-terminal fragment and a 32-residue carboxyl-terminal biologically active peptide. CNP is the most conserved natriuretic peptide. Human proCNP contains 103 residues, and the intracellular endoprotease furin has been shown to process proCNP to the mature 53-amino-acid peptide in vitro. In some tissues, CNP-53 is cleaved to CNP-22 by an unknown extracellular enzyme. CNP-53 is the major form in the brain, endothelial cells, and heart, whereas CNP-22 predominates in human plasma and cerebral spinal fluid1.
Mode of Action
Natriuretic peptides elicit their physiological responses through the synthesis of cGMP, a classic intracellular second messenger. There are three known natriuretic peptide binding proteins in mammals: NPR-A, NPR-B, and NPR-C. They are also known as GC-A, GC-B, and the clearance receptor, or as NPR1, NPR2, and NPR3, respectively. NPR-A and NPR-B represent two of the five transmembrane guanylyl cyclases found in humans. The third natriuretic peptide receptor, NPR-C, does not possess any known intrinsic enzymatic activity.
Hypothetical model for NPR-A and NPR-B activation and desensitization:
Three states of receptor activation are labeled "basal," "active," and "desensitized." In the basal state, NPR-A and NPR-B are higher ordered oligomers. In the basal state, they are phosphorylated on five (NPR-B) or six (NPR-A) known sites within the kinase homology domain. It is hypothesized that phosphorylation "licenses" the receptor for hormonal activation. Natriuretic peptide (NP) binding to the highly phosphorylated, inactive basal receptor induces a conformational change that brings eventually brings about the dimerization of guanylyl cyclase domains. Prolonged ligand exposure stimulates receptor dephosphorylation, which results in reduced activity via a process called desensitization. The dephosphorylation primarily results from inhibition of the phosphorylation process. Release of ligand and rephosphorylation returns the enzyme to its basal state1.
Functions
Natriuretic peptides are often described simply as peptides involved in the regulation of blood pressure and volume. However, the effects of these peptides are widespread, and their levels change in response to a variety of pathological conditions.
Effects of the ANP/NPR-A system on blood pressure:
Although ANP was initially suggested to regulate blood pressure in a salt-sensitive manner, more recent data suggest that this is not the case. Its combined effects on intravascular volume, vasorelaxation, natriuresis, and diuresis mediate the hypotensive nature of ANP.
Effects of ANP and BNP on cardiac hypertrophy and fibrosis:
ANP and BNP have direct effects on the heart. Recent evidence suggests that the cardiac fibrosis involves matrix metalloproteinases (MMPs) which are in turn regulated by both ANP and BNP. Several reports indicate that the ANP/BNP/NPR-A system inhibits pressure-induced cardiac remodeling as well.
Effects of ANP on natriuresis and diuresis:
In the kidney, ANP increases glomerular filtration rate, inhibits sodium and water reabsorption, and reduces renin secretion.
Effects of CNP on vascular relaxation and remodeling:
The ability of the cardiac natriuretic peptides to relax precontracted aortic rings requires NPR-A. CNP relaxes aortic rings by a process that does not require NPR-A, presumably by activating NPR-B.
Effects of natriuretic peptides in the lung:
All three natriuretic peptide receptors are highly expressed in the lung. ANP stimulates the dilation of pulmonary airways and blood vessels. Infusion or inhalation of ANP stimulates bronchodilation in normal and asthmatic patients. CNP also reduces pulmonary hypertension and fibrosis.
ANP-dependent antagonism of the renin-aldosterone system:
ANP regulates blood pressure, in part, through the inhibition of the renin-angiotensin II-aldosterone system.
Effects of ANP on fat metabolism:
ANP-stimulated lipolysis is specific to primates presumably because primates contain a higher NPR-A to NPR-C ratio.
Neurological effects of natriuretic peptides:
All natriuretic peptides and natriuretic peptide receptors have been found in the brain, although CNP and NPR-B appear to be particularly abundant. Consistent with the systemic volume-depleting effects, injection of ANP into the third ventricle of the hypothalamus inhibits water intake induced by overnight dehydration or angiotensin II exposure.
Immunological effects of natriuretic peptides:
Natriuretic peptides and their receptors are found in many immune cells. Current evidence suggests a role for ANP in the allergen response of asthma and in immune-related post ischemic damage.
The CNP/NPR-B/cGMP/PKGII system and long bone growth:
The most obvious physiological effect of CNP is to stimulate long bone growth. It regulates many types of bone cells, but its major target appears to be the chondrocyte1.
Therapeutic applications of natriuretic peptides:
BNP and N-terminal-proBNP have become important diagnostic tools for assessing patients who present acutely with dyspnea. Natriuretic peptide levels have important prognostic value in multiple clinical settings, including in patients with stable coronary artery disease and with acute coronary syndromes. In patients with decompensated heart failure due to volume overload, a treatment-induced drop in wedge pressure is often accompanied by a rapid drop in NP levels3.
References
1.Lincoln R. Potter, Sarah Abbey-Hosch and Deborah M. Dickey(2006). Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions. Endocrine Reviews, 27(1):47-72.
2.de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981). A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci., 28(1):89-94.
3.Daniels LB, Maisel AS (2007). Natriuretic Peptides. J Am Coll Cardiol., 50(25):2357-2368.
Friday, September 4, 2009
Myosin
Definition
Myosin is the most abundant protein in muscle fibrils, responsible for the elastic and contractile properties of muscle. It combines with actin to form actomyosin.
Discovery
A viscous protein was extracted from muscle with concentrated salt solution by Kühne (1864), who called it “myosin” and considered it responsible for the rigor state of muscle1. Muralt and Edsall (1930) showed that the “myosin” in solution had a strong flow birefringence with indications that the particles were uniform in size and shape2. In 1935, Weber (1935) developed a new technique for the in vitro study of contraction. He squirted “myosin” dissolved in high salt into water where it formed threads that became strongly birefringent upon drying 3.
Structural Characteristics
Myosin is a large asymmetric molecule; it has a long tail and two globular heads. The tail is about 1,600 Å long and 20 Å wide. Each head is about 165 Å long, 65 Å wide and 40 Å deep at its thickest part. The molecular weight of myosin is about 500kDa. In strong denaturing solutions, such as 5M guanidine-HCl or 8M urea, myosin dissociates into six polypeptide chains: two heavy chains (molecular weight of each heavy chain about 200 kDa) and four light chains (two with a molecular weight of 20 kDa, one with 15 kDa and another with 25 kDa). The two heavy chains are wound around each other to form a double helical structure. At one end both chains are folded into separate globular structures to form the two heads. In the muscle, the long tail portion forms the backbone of the thick filament and the heads protrude as cross bridges toward the thin filament. Each head contains two light chains. At low ionic strength, e.g. 0.03M KCl, myosin precipitates and forms myosin filaments. Electron micrographs reveal the specific structure of the filaments that is their central shaft and side projections. Myofibrils are tiny muscle fibers, prepared by homogenization of freshly dissected muscle in physiological salt solution. Myofibrils contain the contractile (myosin and actin) and the regulatory proteins (tropomyosin and troponin) of muscle.
Mode of Action
Muscles generate force and shortening in a cyclical interaction between the myosin head domains projecting from the myosin filaments and the adjacent actin filaments. Although many features of the dynamic performance of muscle are determined by the rates of attachment and detachment of myosin and actin, the primary event in force generation is thought to be a conformational change or 'working stroke' in the actin-bound myosin head 4. In the absence of calcium ions, tropomyosin blocks access to the myosin binding site of actin. When calcium binds to troponin, the positions of troponin and tropomyosin are altered on the thin filament and myosin then has access to its binding site on actin. Myosin hydrolyzes ATP and undergoes a conformational change into a high-energy state. The head group of myosin binds to actin forming a cross-bridge between the thick and thin filaments. The energy stored by myosin is released, and ADP and inorganic phosphate dissociate from myosin. The resulting relaxation of the myosin molecule entails rotation of the globular head, which induces longitudinal sliding of the filaments. When the calcium level decreases, troponin locks tropomyosin in the blocking position and the thin filament slides back to the resting state 5.
Functions
Myosin has multiple functions - Filament formation, ATPase activity, and reversible combination with actin. The use of proteolytic enzymes revealed different regions of the myosin molecule were responsible for each of these different functions.
Myosin-actin binding - One of the biologically important properties of myosin is its ability to combine with actin. The complex formed is called actomyosin. The actin binding by myosin is highly specific; no other protein can substitute actin. Physiologically, when actin and myosin combine the muscle produces force. There are several methods to measure the stoichiometry of actin to myosin combination.
ATPase activity of myosin - A Russian husband wife team, Engelhardt and Lyubimova, made the important discovery in 1939 that myosin is an enzyme that hydrolyzes ATP6. It was already known that ATP is the universal energy donor in living cells, thus Engelhardt and Lyubimova created the term mechanochemistry i.e. the contractile protein myosin that carries out the work also liberates the energy necessary for the work.
Myosin filament - At low ionic strength, e.g. 0.03M KCl, myosin precipitates and forms filaments. Since individual myosin molecules have a globular region at one end only, the filaments are formed by anti parallel association of myosin molecules. All the molecules in one half filaments are oriented in one direction and all those in the other half of the filaments are oriented in the opposite direction. Thus, in the middle of the filament the tails of antiparallel molecules overlap yielding a bare central shaft, and globular regions are projected at both ends of the filament7.
ATPase activity of myosin and speed of muscle shortening - The ATPase activity of myosin was determined in 25 different muscles with a 250-fold variation in the speed of shortening. A correlation was found between the ATPase activity of myosin and the speed of shortening. This suggests that the myosin ATPase determines the speed of muscle shortening 8.
References
1.Kühne, W. (1864). Untersuchungen über das Protoplasma und die Contractilitat. W. Engelmann, Leipzig.
2.Von Muralt, A. L., and Edsall, J. T. (1930). Studies in the physical chemistry of muscle globulin. J. Biol. Chem., 89:315 -350.
3.Weber, H.H. 1935. Der feinbau und die mechanischen eigenschaften des myosin-fadens. Arch. Physiol. 235:205–233.
4.Szent-Györgyi AG (2004). Early History of the Biochemistry of Muscle Contraction. J. Gen. Physiol., 123(6): 631–641.
5.Book : Neurobiology, molecules, cells and system By Gary G .Matthews.
6.Engelhardt, V.A., and M.N. Lyubimova (1939). Myosin and adenosinetriphosphatase. Nature., 144:668-669.
7.Hidalgo C, Padron R, Horowitz R, Zhao FG, Craig R (2001). Purification of native myosin filaments from muscle. Biophys. J., 81(5):2817-2826.
8.Bárány, M. (1967). ATPase activity of myosin correlated with speed of muscle shortening. J. Gen. Physiol., 50(6):197-218.
Myosin is the most abundant protein in muscle fibrils, responsible for the elastic and contractile properties of muscle. It combines with actin to form actomyosin.
Discovery
A viscous protein was extracted from muscle with concentrated salt solution by Kühne (1864), who called it “myosin” and considered it responsible for the rigor state of muscle1. Muralt and Edsall (1930) showed that the “myosin” in solution had a strong flow birefringence with indications that the particles were uniform in size and shape2. In 1935, Weber (1935) developed a new technique for the in vitro study of contraction. He squirted “myosin” dissolved in high salt into water where it formed threads that became strongly birefringent upon drying 3.
Structural Characteristics
Myosin is a large asymmetric molecule; it has a long tail and two globular heads. The tail is about 1,600 Å long and 20 Å wide. Each head is about 165 Å long, 65 Å wide and 40 Å deep at its thickest part. The molecular weight of myosin is about 500kDa. In strong denaturing solutions, such as 5M guanidine-HCl or 8M urea, myosin dissociates into six polypeptide chains: two heavy chains (molecular weight of each heavy chain about 200 kDa) and four light chains (two with a molecular weight of 20 kDa, one with 15 kDa and another with 25 kDa). The two heavy chains are wound around each other to form a double helical structure. At one end both chains are folded into separate globular structures to form the two heads. In the muscle, the long tail portion forms the backbone of the thick filament and the heads protrude as cross bridges toward the thin filament. Each head contains two light chains. At low ionic strength, e.g. 0.03M KCl, myosin precipitates and forms myosin filaments. Electron micrographs reveal the specific structure of the filaments that is their central shaft and side projections. Myofibrils are tiny muscle fibers, prepared by homogenization of freshly dissected muscle in physiological salt solution. Myofibrils contain the contractile (myosin and actin) and the regulatory proteins (tropomyosin and troponin) of muscle.
Mode of Action
Muscles generate force and shortening in a cyclical interaction between the myosin head domains projecting from the myosin filaments and the adjacent actin filaments. Although many features of the dynamic performance of muscle are determined by the rates of attachment and detachment of myosin and actin, the primary event in force generation is thought to be a conformational change or 'working stroke' in the actin-bound myosin head 4. In the absence of calcium ions, tropomyosin blocks access to the myosin binding site of actin. When calcium binds to troponin, the positions of troponin and tropomyosin are altered on the thin filament and myosin then has access to its binding site on actin. Myosin hydrolyzes ATP and undergoes a conformational change into a high-energy state. The head group of myosin binds to actin forming a cross-bridge between the thick and thin filaments. The energy stored by myosin is released, and ADP and inorganic phosphate dissociate from myosin. The resulting relaxation of the myosin molecule entails rotation of the globular head, which induces longitudinal sliding of the filaments. When the calcium level decreases, troponin locks tropomyosin in the blocking position and the thin filament slides back to the resting state 5.
Functions
Myosin has multiple functions - Filament formation, ATPase activity, and reversible combination with actin. The use of proteolytic enzymes revealed different regions of the myosin molecule were responsible for each of these different functions.
Myosin-actin binding - One of the biologically important properties of myosin is its ability to combine with actin. The complex formed is called actomyosin. The actin binding by myosin is highly specific; no other protein can substitute actin. Physiologically, when actin and myosin combine the muscle produces force. There are several methods to measure the stoichiometry of actin to myosin combination.
ATPase activity of myosin - A Russian husband wife team, Engelhardt and Lyubimova, made the important discovery in 1939 that myosin is an enzyme that hydrolyzes ATP6. It was already known that ATP is the universal energy donor in living cells, thus Engelhardt and Lyubimova created the term mechanochemistry i.e. the contractile protein myosin that carries out the work also liberates the energy necessary for the work.
Myosin filament - At low ionic strength, e.g. 0.03M KCl, myosin precipitates and forms filaments. Since individual myosin molecules have a globular region at one end only, the filaments are formed by anti parallel association of myosin molecules. All the molecules in one half filaments are oriented in one direction and all those in the other half of the filaments are oriented in the opposite direction. Thus, in the middle of the filament the tails of antiparallel molecules overlap yielding a bare central shaft, and globular regions are projected at both ends of the filament7.
ATPase activity of myosin and speed of muscle shortening - The ATPase activity of myosin was determined in 25 different muscles with a 250-fold variation in the speed of shortening. A correlation was found between the ATPase activity of myosin and the speed of shortening. This suggests that the myosin ATPase determines the speed of muscle shortening 8.
References
1.Kühne, W. (1864). Untersuchungen über das Protoplasma und die Contractilitat. W. Engelmann, Leipzig.
2.Von Muralt, A. L., and Edsall, J. T. (1930). Studies in the physical chemistry of muscle globulin. J. Biol. Chem., 89:315 -350.
3.Weber, H.H. 1935. Der feinbau und die mechanischen eigenschaften des myosin-fadens. Arch. Physiol. 235:205–233.
4.Szent-Györgyi AG (2004). Early History of the Biochemistry of Muscle Contraction. J. Gen. Physiol., 123(6): 631–641.
5.Book : Neurobiology, molecules, cells and system By Gary G .Matthews.
6.Engelhardt, V.A., and M.N. Lyubimova (1939). Myosin and adenosinetriphosphatase. Nature., 144:668-669.
7.Hidalgo C, Padron R, Horowitz R, Zhao FG, Craig R (2001). Purification of native myosin filaments from muscle. Biophys. J., 81(5):2817-2826.
8.Bárány, M. (1967). ATPase activity of myosin correlated with speed of muscle shortening. J. Gen. Physiol., 50(6):197-218.
Thursday, September 3, 2009
Myelin Basic Protein Fragments (MBPs)
Definition
One of the two major classes of myelin proteins is the myelin basic proteins (MBPs), a family of proteins derived by alternative splicing of the MBP gene.
Discovery
Campagnoni et al identified a novel transcription unit of 105 kbp (called the Golli-mbp gene) that encompasses the mouse myelin basic protein (MBP) gene. Three unique exons within this gene are alternatively spliced into MBP exons and introns to produce a family of MBP gene- related mRNAs that are under individual developmental regulation. These mRNAs are temporally expressed within cells of the oligodendrocyte lineage at progressive stages of differentiation. Thus, the MBP gene is a part of a more complex gene structure, the products of which play a role in oligodendrocyte differentiation prior to myelination1.
Structural Characteristics
There are multiple isoforms of MBP that are produced through the translation of separate mRNAs, resulting in a heterogeneous population of MBP structures. MBP is an ‘intrinsically unstructured’ protein with a high proportion ( 75%) of random coil, but postulated to have core elements of ß-sheet and a-helix. In solution, MBP is “intrinsically unstructured” (or “natively unfolded”). Upon binding to detergents or lipids, the levels of beta-sheet and especially alpha-helical structure increase dramatically. MBP was an amphipathic alpha-helix located at the interface between the oligodendrocyte cytoplasm and the membrane. In a solution circular dichroism (CD) and Fourier transform infrared spectroscopic study, MBP peptides were found to have both helix and sheet structures in methanol, with the latter increasing in amount in progressively shorter peptides 2, 3.
Mode of Action
In order to clarify insulinotropic effects of the myelin basic protein (MBP) Kolehmainen et al studied mode of association and distribution of MBP in the pancreatic islets and tested the insulin-releasing activity of various MBP peptides. Rat pancreatic islets were first stimulated in a static incubation with 10 µM bovine MBP (bMBP) at a substimulatory (3.5 mM) glucose concentration. The islets exposed to MBP released significantly more insulin and glucagon in a second incubation in the absence of added stimulant and in the presence of 11.5 mM arginine than the incubated, non-stimulated islets and islets initially stimulated with 15 mM glucose. Response to stimulation with 15 mM glucose in the second incubation by islets exposed first to MBP was impaired compared to incubated, non-stimulated islets. Immunoelectron microscopy showed that MBP had entered into the islet cells and associated with membranes of intracellular vacuoles, most of which represented enlarged, often fused insulin granules. MBP was also present at the islet edge and in the intercellular spaces. Of the purified MBP peptides of sizes of 4.8–13.6 kDa, produced from the digestion with brain acid proteinase and with pepsin and covering the entire bMBP sequence, only the large peptides (1–88, 9.8 kDa and 43–169, 13.6 kDa) stimulated insulin secretion significantly. Heterogeneous peptide mixtures, obtained from a time-course digestion of bMBP by myelin calcium-activated neutral protease, consisting of peptides of approximate molecular weights of 8–11 kDa and larger, also stimulated insulin release. The glucagon-releasing activity of MBP peptides was low and followed the same pattern as the insulin-releasing activity. These results suggest that MBP-induced fusion of the membranes of hormone granules is involved in MBP-induced insulin release. The hormone-releasing activity of the large peptides in addition to that of the intact molecule is explained as being due to the ability of these peptides to associate with membranes. MBP-induced hormone release and related effects could be associated with neuropathological conditions such as stroke and multiple sclerosis 4.
Functions
MBP plays a key role in the pathology of MS, although its mechanism of action has remained unclear. Antigenically related MBP was isolated from the cerebrospinal fluid of patients with multiple sclerosis (MS) 5. Induction of experimental allergic encephalomyelitis (EAE) with MBP produced a monophasic inflammatory disease process in guinea pigs with minimal demyelination, whereas the addition of galactocerebrosides or the use of whole myelin produced EAE with demyelination, suggesting that MBP plays a role in demyelination when in synergy with myelin lipids 6. It was demonstrated that a single transfer of MBP-sensitized T cells from animals with EAE produced a relapsing disease process in mice with both inflammation and demyelination, similar to what is found in MS. This discovery suggests MBP isoforms as candidate autoantigens7.
References
1.Campagnoni AT, Pribyl TM, Campagnoni CW, Kampf K, Amur- Umarjee S, Landry CF, Handley VW, Newman SL, Garbay B, Kitamura K (1993). Structure and developmental regulation of golli-mbp, a 105 kb gene that encompasses the myelin basic protein gene and is expressed in cells in the oligodendrocyte lineage in the brain. J Biol Chem., 268: 4930-4938.
2.Hill CM, Bates IR, White GF, Hallett, FR, Harauz G (2002). Effects of the osmolyte trimethylamine-N-oxide on conformation, self-association, and two-dimensional crystallization of myelin basic protein. J Struct Biol., 139: 13-26.
3.Whitaker JN, Moscarello MA, Herman PK, Epand RM, Surewicz, WK (1990) Conformational correlates of the epitopes of human myelin basic protein peptide 80-89. J. Neurochem., 55:568-576.
4.Kolehmainen E. (1995). Evidence supporting membrane fusion as the mechanism of myelin basic protein-induced insulin release from rat pancreatic islets. Neurochem Intl., 26 (5):503-518.
5.Carson JH, Barbarese E, Braun PE, McPherson TA (1978). Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein. PNAS, 75(4):1976–1978.
6.Raine CS, Traugott U, Farooq M, Bornstein MB, Norton WT (1981). Augmentation of immune-mediated demyelination by lipid haptens. Lab. Invest., 45:174–182.
7.Mokhtarian F, McFarlin DE, Raine CS (1984). Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature, 309:356–358.
One of the two major classes of myelin proteins is the myelin basic proteins (MBPs), a family of proteins derived by alternative splicing of the MBP gene.
Discovery
Campagnoni et al identified a novel transcription unit of 105 kbp (called the Golli-mbp gene) that encompasses the mouse myelin basic protein (MBP) gene. Three unique exons within this gene are alternatively spliced into MBP exons and introns to produce a family of MBP gene- related mRNAs that are under individual developmental regulation. These mRNAs are temporally expressed within cells of the oligodendrocyte lineage at progressive stages of differentiation. Thus, the MBP gene is a part of a more complex gene structure, the products of which play a role in oligodendrocyte differentiation prior to myelination1.
Structural Characteristics
There are multiple isoforms of MBP that are produced through the translation of separate mRNAs, resulting in a heterogeneous population of MBP structures. MBP is an ‘intrinsically unstructured’ protein with a high proportion ( 75%) of random coil, but postulated to have core elements of ß-sheet and a-helix. In solution, MBP is “intrinsically unstructured” (or “natively unfolded”). Upon binding to detergents or lipids, the levels of beta-sheet and especially alpha-helical structure increase dramatically. MBP was an amphipathic alpha-helix located at the interface between the oligodendrocyte cytoplasm and the membrane. In a solution circular dichroism (CD) and Fourier transform infrared spectroscopic study, MBP peptides were found to have both helix and sheet structures in methanol, with the latter increasing in amount in progressively shorter peptides 2, 3.
Mode of Action
In order to clarify insulinotropic effects of the myelin basic protein (MBP) Kolehmainen et al studied mode of association and distribution of MBP in the pancreatic islets and tested the insulin-releasing activity of various MBP peptides. Rat pancreatic islets were first stimulated in a static incubation with 10 µM bovine MBP (bMBP) at a substimulatory (3.5 mM) glucose concentration. The islets exposed to MBP released significantly more insulin and glucagon in a second incubation in the absence of added stimulant and in the presence of 11.5 mM arginine than the incubated, non-stimulated islets and islets initially stimulated with 15 mM glucose. Response to stimulation with 15 mM glucose in the second incubation by islets exposed first to MBP was impaired compared to incubated, non-stimulated islets. Immunoelectron microscopy showed that MBP had entered into the islet cells and associated with membranes of intracellular vacuoles, most of which represented enlarged, often fused insulin granules. MBP was also present at the islet edge and in the intercellular spaces. Of the purified MBP peptides of sizes of 4.8–13.6 kDa, produced from the digestion with brain acid proteinase and with pepsin and covering the entire bMBP sequence, only the large peptides (1–88, 9.8 kDa and 43–169, 13.6 kDa) stimulated insulin secretion significantly. Heterogeneous peptide mixtures, obtained from a time-course digestion of bMBP by myelin calcium-activated neutral protease, consisting of peptides of approximate molecular weights of 8–11 kDa and larger, also stimulated insulin release. The glucagon-releasing activity of MBP peptides was low and followed the same pattern as the insulin-releasing activity. These results suggest that MBP-induced fusion of the membranes of hormone granules is involved in MBP-induced insulin release. The hormone-releasing activity of the large peptides in addition to that of the intact molecule is explained as being due to the ability of these peptides to associate with membranes. MBP-induced hormone release and related effects could be associated with neuropathological conditions such as stroke and multiple sclerosis 4.
Functions
MBP plays a key role in the pathology of MS, although its mechanism of action has remained unclear. Antigenically related MBP was isolated from the cerebrospinal fluid of patients with multiple sclerosis (MS) 5. Induction of experimental allergic encephalomyelitis (EAE) with MBP produced a monophasic inflammatory disease process in guinea pigs with minimal demyelination, whereas the addition of galactocerebrosides or the use of whole myelin produced EAE with demyelination, suggesting that MBP plays a role in demyelination when in synergy with myelin lipids 6. It was demonstrated that a single transfer of MBP-sensitized T cells from animals with EAE produced a relapsing disease process in mice with both inflammation and demyelination, similar to what is found in MS. This discovery suggests MBP isoforms as candidate autoantigens7.
References
1.Campagnoni AT, Pribyl TM, Campagnoni CW, Kampf K, Amur- Umarjee S, Landry CF, Handley VW, Newman SL, Garbay B, Kitamura K (1993). Structure and developmental regulation of golli-mbp, a 105 kb gene that encompasses the myelin basic protein gene and is expressed in cells in the oligodendrocyte lineage in the brain. J Biol Chem., 268: 4930-4938.
2.Hill CM, Bates IR, White GF, Hallett, FR, Harauz G (2002). Effects of the osmolyte trimethylamine-N-oxide on conformation, self-association, and two-dimensional crystallization of myelin basic protein. J Struct Biol., 139: 13-26.
3.Whitaker JN, Moscarello MA, Herman PK, Epand RM, Surewicz, WK (1990) Conformational correlates of the epitopes of human myelin basic protein peptide 80-89. J. Neurochem., 55:568-576.
4.Kolehmainen E. (1995). Evidence supporting membrane fusion as the mechanism of myelin basic protein-induced insulin release from rat pancreatic islets. Neurochem Intl., 26 (5):503-518.
5.Carson JH, Barbarese E, Braun PE, McPherson TA (1978). Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein. PNAS, 75(4):1976–1978.
6.Raine CS, Traugott U, Farooq M, Bornstein MB, Norton WT (1981). Augmentation of immune-mediated demyelination by lipid haptens. Lab. Invest., 45:174–182.
7.Mokhtarian F, McFarlin DE, Raine CS (1984). Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature, 309:356–358.
Tuesday, August 25, 2009
Milk Peptides
Definition
Milk peptides are formed from milk proteins through enzymatic breakdown by digestive enzymes or by the proteinases of lactobacilli during the fermentation of milk. These peptides directly influence numerous biological processes evoking behavioral, gastrointestinal, hormonal, immunological, neurological, and nutritional responses.
Discovery
The major protein fractions in bovine milk include a-LA, ß-LG, caseins, immunoglobulins, lactoferrin, proteose- peptide fractions (heat-stable, acid soluble phosphoglycoproteins and minor whey proteins such as transferrin and serum albumin. Antimicrobial milk proteins, such as lactoferrin, were described in early literature1. Casecidin, obtained by chymosin digestion of casein at neutral pH, was among the first defense peptides actually purified and exhibited activity in vitro against Staphylococcus, Sarcina, Bacillus subtilis, Diplococcus pneumoniae, and Streptococcus pyogenes2. Milk also contains peptides that exhibit antifungal properties like lactoferrin or its peptides (ex. lactoferricin B., in combination with azole antifungal agents, has been demonstrated with Candida albicans3.
Stuctural Characteristics
Milk peptides have a high content of negative charges they will efficiently bind divalent cations with the formation of soluble complexes. Complexes of peptides and minerals of Fe, Mg, Mn, Cu and Se are reported. The high content of negative charges makes these phosphopeptides resistant to further hydrolysis. Milk caseins are easily degradable proteins due to their random coil structure. The whey proteins, b-lactoglobulin, a-lactalbumin and lactoferrin also give rise to peptides with mineral binding abilities. These proteins are regarded as more resistant to enzymatic attack and undergo hydrolysis much more slowly than the caseins4.
Mode of action
Milk peptides may affect mucosal immunity possibly by guiding local immunity until it develops its full functionality5. Several milk peptides have been shown to have antihypertensive effects in animal and in clinical studies. The most studied mechanism underlying the antihypertensive effects of milk peptides is inhibition of angiotensin-converting enzyme6. Angiotensin-converting enzyme inhibition (ACE. is an enzyme that plays a crucial role in the function of the renin-angiotensin system (RAS). The RAS is an important regulator of blood pressure and fluid and electrolyte balance. In the RAS, angiotensin I is converted to angiotensin II by ACE. Angiotensin II is a strong vasoconstrictor that induces release of aldosterone and therefore increases sodium concentration and furthers the blood pressure. ACE inhibitors have 2 effects on the renin-angiotensin system. They reduce production of angiotensin II and inhibit the degradation of the vasodilator.
Several milk peptides have opioid-like activities are derived from ??casein, called ?-exorphins, and those derived from ?-casein are called casoxins. These peptides have been shown to lower blood pressure. Because the antihypertensive effect of ?-lactorphin was completely prevented by an opioid receptor antagonist naloxone, it has been proposed that the antihypertensive effect is mediated via opioid receptors.
Functions
Antimicrobial Peptides - Milk contains a variety of components that provide immunological protection and facilitate the development of neonatal immune competence6. Lactoferrin is another milk bioactive compound with nutritional and health promoting properties; it modulates the microbial intestinal environment, displays anti-microbial activity against various pathogens and stimulates the establishment of beneficial microflora.
Antihypertensive Peptides (ACE Inhibitors) - Antihypertensive peptides inhibit the angiotensin converting enzyme (ACE), ACE converts angiotensin I to angiotensin II, increasing blood pressure and aldersterone, and inactivating the depressor action of bradykinin7.
Antithrombotic Peptides- Antithrombotic peptides are present in milk, involved in milk clotting, defined by the interaction of ?-CN with chymosin and blood clotting processes8.
Caseinophosphopeptides- Casein phosphopeptides (CPP) have been identified after trypsin release from as1-, as2-, and ß-CN. This complex formation results in an increased solubility which, in turn, provides enhanced absorption of calcium across the distal small intestines of animals fed casein diets in comparison to control animals fed soy-based diets7.
Immunomodulatory Peptides - Immunomodulatory milk peptides affect both the immune system and cell proliferation responses. ß-casokinins inhibit ACE enzymes that are responsible for inactivating bradykinin, a hormone with immune enhancing effects7.
References
1. Bullen JJ, Rogers HJ, Leigh L (1972). Iron binding proteins in milk and resistance to E. coli infections in infants. Br. Med, 1: 69–75.
2. Lahov E and W Regelson (1996) Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Food Chem. Toxicol, 34: 131–145.
3. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H (1996). Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol, 40: 821–825.
4. Vegarud GE, Langsrud T, Svenning C (2000.. Mineral-binding milk proteins and peptides; occurrence, biochemical and technological characteristics. British Journal of Nutrition, 84(1): 91-98.
5. Politis I and Chronopoulou R (2007). Milk Peptides and Immune Response in the Neonate. Advances in Experimental Medicine and Biology, 606: 253-269.
Milk peptides are formed from milk proteins through enzymatic breakdown by digestive enzymes or by the proteinases of lactobacilli during the fermentation of milk. These peptides directly influence numerous biological processes evoking behavioral, gastrointestinal, hormonal, immunological, neurological, and nutritional responses.
Discovery
The major protein fractions in bovine milk include a-LA, ß-LG, caseins, immunoglobulins, lactoferrin, proteose- peptide fractions (heat-stable, acid soluble phosphoglycoproteins and minor whey proteins such as transferrin and serum albumin. Antimicrobial milk proteins, such as lactoferrin, were described in early literature1. Casecidin, obtained by chymosin digestion of casein at neutral pH, was among the first defense peptides actually purified and exhibited activity in vitro against Staphylococcus, Sarcina, Bacillus subtilis, Diplococcus pneumoniae, and Streptococcus pyogenes2. Milk also contains peptides that exhibit antifungal properties like lactoferrin or its peptides (ex. lactoferricin B., in combination with azole antifungal agents, has been demonstrated with Candida albicans3.
Stuctural Characteristics
Milk peptides have a high content of negative charges they will efficiently bind divalent cations with the formation of soluble complexes. Complexes of peptides and minerals of Fe, Mg, Mn, Cu and Se are reported. The high content of negative charges makes these phosphopeptides resistant to further hydrolysis. Milk caseins are easily degradable proteins due to their random coil structure. The whey proteins, b-lactoglobulin, a-lactalbumin and lactoferrin also give rise to peptides with mineral binding abilities. These proteins are regarded as more resistant to enzymatic attack and undergo hydrolysis much more slowly than the caseins4.
Mode of action
Milk peptides may affect mucosal immunity possibly by guiding local immunity until it develops its full functionality5. Several milk peptides have been shown to have antihypertensive effects in animal and in clinical studies. The most studied mechanism underlying the antihypertensive effects of milk peptides is inhibition of angiotensin-converting enzyme6. Angiotensin-converting enzyme inhibition (ACE. is an enzyme that plays a crucial role in the function of the renin-angiotensin system (RAS). The RAS is an important regulator of blood pressure and fluid and electrolyte balance. In the RAS, angiotensin I is converted to angiotensin II by ACE. Angiotensin II is a strong vasoconstrictor that induces release of aldosterone and therefore increases sodium concentration and furthers the blood pressure. ACE inhibitors have 2 effects on the renin-angiotensin system. They reduce production of angiotensin II and inhibit the degradation of the vasodilator.
Several milk peptides have opioid-like activities are derived from ??casein, called ?-exorphins, and those derived from ?-casein are called casoxins. These peptides have been shown to lower blood pressure. Because the antihypertensive effect of ?-lactorphin was completely prevented by an opioid receptor antagonist naloxone, it has been proposed that the antihypertensive effect is mediated via opioid receptors.
Functions
Antimicrobial Peptides - Milk contains a variety of components that provide immunological protection and facilitate the development of neonatal immune competence6. Lactoferrin is another milk bioactive compound with nutritional and health promoting properties; it modulates the microbial intestinal environment, displays anti-microbial activity against various pathogens and stimulates the establishment of beneficial microflora.
Antihypertensive Peptides (ACE Inhibitors) - Antihypertensive peptides inhibit the angiotensin converting enzyme (ACE), ACE converts angiotensin I to angiotensin II, increasing blood pressure and aldersterone, and inactivating the depressor action of bradykinin7.
Antithrombotic Peptides- Antithrombotic peptides are present in milk, involved in milk clotting, defined by the interaction of ?-CN with chymosin and blood clotting processes8.
Caseinophosphopeptides- Casein phosphopeptides (CPP) have been identified after trypsin release from as1-, as2-, and ß-CN. This complex formation results in an increased solubility which, in turn, provides enhanced absorption of calcium across the distal small intestines of animals fed casein diets in comparison to control animals fed soy-based diets7.
Immunomodulatory Peptides - Immunomodulatory milk peptides affect both the immune system and cell proliferation responses. ß-casokinins inhibit ACE enzymes that are responsible for inactivating bradykinin, a hormone with immune enhancing effects7.
References
1. Bullen JJ, Rogers HJ, Leigh L (1972). Iron binding proteins in milk and resistance to E. coli infections in infants. Br. Med, 1: 69–75.
2. Lahov E and W Regelson (1996) Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Food Chem. Toxicol, 34: 131–145.
3. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H (1996). Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol, 40: 821–825.
4. Vegarud GE, Langsrud T, Svenning C (2000.. Mineral-binding milk proteins and peptides; occurrence, biochemical and technological characteristics. British Journal of Nutrition, 84(1): 91-98.
5. Politis I and Chronopoulou R (2007). Milk Peptides and Immune Response in the Neonate. Advances in Experimental Medicine and Biology, 606: 253-269.
Kassinins
Definition
Dodecapeptide tachykinin that is kassinin is found in the central nervous system of the amphibian Kassina senegalensis. It is similar in structure and action to other tachykinins, but it is especially effective in contracting smooth muscle tissue and stimulating the micturition reflex.
Discovery
In 1964, Erspamer et al., first demonstrated the occurrence of bioactive peptide, kassinin in amphibian skin1. A biosynthetic precursor of kassinin cDNA encoding the novel kassinin analog (Thr2, Ile9)-kassinin was identified in skin secretion of amphibian2. In 1983, two new mammalian tachykinins, neurokinin A and neurokinin B, were discovered in the porcine spinal cord. Their pharmacological actions more closely resemble those of the amphibian tachykinin kassinin and the molluscan tachykinin eledoisin3.
Structural Characteristics
Tachykinins are among the most widely-studied families of regulatory peptides characterized by a highly-conserved C-terminal -Phe-X-Gly-Leu-Met amide motif, which also constitutes the essential bioactive core. Both the aqueous and lipid-induced structure of kassinin, has been studied by Rani et al., (2001). Water kassinin prefers to be in an extended chain conformation, in the presence of perdeuterated dodecylphosphocholine (DPC) micelles, a membrane model system, helical conformation is induced in the central core and C-terminal region (K4-M12) of the peptide. N-terminus though less defined also displays some degree of order and a possible turn structure. The conformation adopted by kassinin in the presence of DPC micelles is consistent with the structural motif typical of neurokinin-1 selective agonists and with that reported for eledoisin in hydrophobic environment4.
Mode of Action
In frog skin, tachykinins stimulate the ion transport, by interacting with NK1-like receptors which can be estimated by measuring the short-circuit current (SCC) value. Kassinin (NK2 preferring in mammals) increases the SCC5. Kassinin also induces concentration-related contractions of the longitudinal muscle of the mouse distal colon. Contractile responses to the tachykinins result from a direct activation of smooth muscle cells. Kassinin evokes a contractile response in the absence of external Ca2+ and their myogenic activity was, to some extent, resistant to the inhibitory effect of nifedipine (a calcium channel blocker). So an additional process, probably the release of an intracellularly bound Ca2+ store, participates in the mechanism by which kassinin contracts the mouse distal colon. After desensitization of the mouse distal colon to Substance P (SP), the contractile activity provoked by SP was totally abolished whilst the responses evoked by kassinin were barely affected. These observations and other experimental findings indirectly support the assumption that the mouse distal colons possess different tachykinin-binding sites6.
Functions
Effect on rat urinary bladder - Synthetic replicates of kassinin are found to be active on rat urinary bladder smooth muscle at nanomolar concentrations2. Kassinin induces concentration-related contractions of the longitudinal muscle of the mouse distal colon.
Effect on endocrine pancreatic function - The effect of kassinin on endocrine pancreatic function was examined in the rat. Kassinin, injected intravenously in graded doses 10, 20, and 30 min before blood collection, significantly increased both plasma insulin and plasma glucagon in a dose-related fashion. The largest dose examined (10 µg) increased plasma insulin by 275% and plasma glucagon by 77% 7.
Synthetic kassinin affects splanchnic circulation - Effects of intravenously administered synthetic kassinin on splanchnic circulation and exocrine pancreatic secretion was examined in six anesthetized dogs. Kassinin caused dose-related increases in the blood flow in superior mesenteric artery and portal vein, and produced an initial increase followed by a decrease in pancreatic blood flow, but did not affect the exocrine pancreatic secretion. This study suggests that kassinin functions as a neuropeptide controlling the splanchnic circulation in mammalian species8.
References
1.Book : Handbook of chemical neuroanatomy. Chapter VI Neurokinin receptors in the CNS by Da-silva R, Mcleod AL, Krause JE.
2.Wang L, Zhou M, Lynch L, Chen T, Walker B, Shaw C (2009). Kassina senegalensis skin tachykinins: Molecular cloning of kassinin and (Thr2, Ile9)-kassinin biosynthetic precursor cDNAs and comparative bioactivity of mature tachykinins on the smooth muscle of rat urinary bladder. Biochimie, 91(5): 613-619.
3.Tan DP and Tsou K (1988). Differential Effects of Tachykinins Injected Intranigrally on Striatal Dopamine Metabolism. Journal of Neurochemistr, 51(5): 1333-1337.
4.Rani CR, Lynn AM, Cowsik SM (2001). Lipid Induced Conformation of the Tachykinin Peptide Kassinin. Journal of Biomolecular Structure and Dynamics, 18 (4): 611-625.
5.Lippe C, Bellantuon V, Ardizzone C, Cassano G (2004). Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin. Peptides, 25(11): 1971-1975.
6.Fontaine J and Lebrun P (1989). Contractile effects of substance P and other tachykinins on the mouse isolated distal colon. Br J Pharmacol, 96(3): 583–590.
7.Gullner HG, Yajimsa H, Harris V, Unger RH (1982). Kassinin: Stimulation of Insulin and Glucagon Secretion in the Rat. Endocrinology, 110 (4): 1246-1248.
8.Doi R, Inoue K, Kogire M, Sumi S, Takaori K, Yun M, Yajima H, Tobe T (1988). Effects of synthetic kassinin on splanchnic circulation and exocrine pancreas in dogs. Peptides, 9(5): 1055-1058.
Dodecapeptide tachykinin that is kassinin is found in the central nervous system of the amphibian Kassina senegalensis. It is similar in structure and action to other tachykinins, but it is especially effective in contracting smooth muscle tissue and stimulating the micturition reflex.
Discovery
In 1964, Erspamer et al., first demonstrated the occurrence of bioactive peptide, kassinin in amphibian skin1. A biosynthetic precursor of kassinin cDNA encoding the novel kassinin analog (Thr2, Ile9)-kassinin was identified in skin secretion of amphibian2. In 1983, two new mammalian tachykinins, neurokinin A and neurokinin B, were discovered in the porcine spinal cord. Their pharmacological actions more closely resemble those of the amphibian tachykinin kassinin and the molluscan tachykinin eledoisin3.
Structural Characteristics
Tachykinins are among the most widely-studied families of regulatory peptides characterized by a highly-conserved C-terminal -Phe-X-Gly-Leu-Met amide motif, which also constitutes the essential bioactive core. Both the aqueous and lipid-induced structure of kassinin, has been studied by Rani et al., (2001). Water kassinin prefers to be in an extended chain conformation, in the presence of perdeuterated dodecylphosphocholine (DPC) micelles, a membrane model system, helical conformation is induced in the central core and C-terminal region (K4-M12) of the peptide. N-terminus though less defined also displays some degree of order and a possible turn structure. The conformation adopted by kassinin in the presence of DPC micelles is consistent with the structural motif typical of neurokinin-1 selective agonists and with that reported for eledoisin in hydrophobic environment4.
Mode of Action
In frog skin, tachykinins stimulate the ion transport, by interacting with NK1-like receptors which can be estimated by measuring the short-circuit current (SCC) value. Kassinin (NK2 preferring in mammals) increases the SCC5. Kassinin also induces concentration-related contractions of the longitudinal muscle of the mouse distal colon. Contractile responses to the tachykinins result from a direct activation of smooth muscle cells. Kassinin evokes a contractile response in the absence of external Ca2+ and their myogenic activity was, to some extent, resistant to the inhibitory effect of nifedipine (a calcium channel blocker). So an additional process, probably the release of an intracellularly bound Ca2+ store, participates in the mechanism by which kassinin contracts the mouse distal colon. After desensitization of the mouse distal colon to Substance P (SP), the contractile activity provoked by SP was totally abolished whilst the responses evoked by kassinin were barely affected. These observations and other experimental findings indirectly support the assumption that the mouse distal colons possess different tachykinin-binding sites6.
Functions
Effect on rat urinary bladder - Synthetic replicates of kassinin are found to be active on rat urinary bladder smooth muscle at nanomolar concentrations2. Kassinin induces concentration-related contractions of the longitudinal muscle of the mouse distal colon.
Effect on endocrine pancreatic function - The effect of kassinin on endocrine pancreatic function was examined in the rat. Kassinin, injected intravenously in graded doses 10, 20, and 30 min before blood collection, significantly increased both plasma insulin and plasma glucagon in a dose-related fashion. The largest dose examined (10 µg) increased plasma insulin by 275% and plasma glucagon by 77% 7.
Synthetic kassinin affects splanchnic circulation - Effects of intravenously administered synthetic kassinin on splanchnic circulation and exocrine pancreatic secretion was examined in six anesthetized dogs. Kassinin caused dose-related increases in the blood flow in superior mesenteric artery and portal vein, and produced an initial increase followed by a decrease in pancreatic blood flow, but did not affect the exocrine pancreatic secretion. This study suggests that kassinin functions as a neuropeptide controlling the splanchnic circulation in mammalian species8.
References
1.Book : Handbook of chemical neuroanatomy. Chapter VI Neurokinin receptors in the CNS by Da-silva R, Mcleod AL, Krause JE.
2.Wang L, Zhou M, Lynch L, Chen T, Walker B, Shaw C (2009). Kassina senegalensis skin tachykinins: Molecular cloning of kassinin and (Thr2, Ile9)-kassinin biosynthetic precursor cDNAs and comparative bioactivity of mature tachykinins on the smooth muscle of rat urinary bladder. Biochimie, 91(5): 613-619.
3.Tan DP and Tsou K (1988). Differential Effects of Tachykinins Injected Intranigrally on Striatal Dopamine Metabolism. Journal of Neurochemistr, 51(5): 1333-1337.
4.Rani CR, Lynn AM, Cowsik SM (2001). Lipid Induced Conformation of the Tachykinin Peptide Kassinin. Journal of Biomolecular Structure and Dynamics, 18 (4): 611-625.
5.Lippe C, Bellantuon V, Ardizzone C, Cassano G (2004). Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin. Peptides, 25(11): 1971-1975.
6.Fontaine J and Lebrun P (1989). Contractile effects of substance P and other tachykinins on the mouse isolated distal colon. Br J Pharmacol, 96(3): 583–590.
7.Gullner HG, Yajimsa H, Harris V, Unger RH (1982). Kassinin: Stimulation of Insulin and Glucagon Secretion in the Rat. Endocrinology, 110 (4): 1246-1248.
8.Doi R, Inoue K, Kogire M, Sumi S, Takaori K, Yun M, Yajima H, Tobe T (1988). Effects of synthetic kassinin on splanchnic circulation and exocrine pancreas in dogs. Peptides, 9(5): 1055-1058.
Kassinins
Definition
Dodecapeptide tachykinin that is kassinin is found in the central nervous system of the amphibian Kassina senegalensis. It is similar in structure and action to other tachykinins, but it is especially effective in contracting smooth muscle tissue and stimulating the micturition reflex.
Discovery
In 1964, Erspamer et al., first demonstrated the occurrence of bioactive peptide, kassinin in amphibian skin1. A biosynthetic precursor of kassinin cDNA encoding the novel kassinin analog (Thr2, Ile9)-kassinin was identified in skin secretion of amphibian2. In 1983, two new mammalian tachykinins, neurokinin A and neurokinin B, were discovered in the porcine spinal cord. Their pharmacological actions more closely resemble those of the amphibian tachykinin kassinin and the molluscan tachykinin eledoisin3.
Structural Characteristics
Tachykinins are among the most widely-studied families of regulatory peptides characterized by a highly-conserved C-terminal -Phe-X-Gly-Leu-Met amide motif, which also constitutes the essential bioactive core. Both the aqueous and lipid-induced structure of kassinin, has been studied by Rani et al., (2001). Water kassinin prefers to be in an extended chain conformation, in the presence of perdeuterated dodecylphosphocholine (DPC) micelles, a membrane model system, helical conformation is induced in the central core and C-terminal region (K4-M12) of the peptide. N-terminus though less defined also displays some degree of order and a possible turn structure. The conformation adopted by kassinin in the presence of DPC micelles is consistent with the structural motif typical of neurokinin-1 selective agonists and with that reported for eledoisin in hydrophobic environment4.
Mode of Action
In frog skin, tachykinins stimulate the ion transport, by interacting with NK1-like receptors which can be estimated by measuring the short-circuit current (SCC) value. Kassinin (NK2 preferring in mammals) increases the SCC5. Kassinin also induces concentration-related contractions of the longitudinal muscle of the mouse distal colon. Contractile responses to the tachykinins result from a direct activation of smooth muscle cells. Kassinin evokes a contractile response in the absence of external Ca2+ and their myogenic activity was, to some extent, resistant to the inhibitory effect of nifedipine (a calcium channel blocker). So an additional process, probably the release of an intracellularly bound Ca2+ store, participates in the mechanism by which kassinin contracts the mouse distal colon. After desensitization of the mouse distal colon to Substance P (SP), the contractile activity provoked by SP was totally abolished whilst the responses evoked by kassinin were barely affected. These observations and other experimental findings indirectly support the assumption that the mouse distal colons possess different tachykinin-binding sites6.
Functions
Effect on rat urinary bladder - Synthetic replicates of kassinin are found to be active on rat urinary bladder smooth muscle at nanomolar concentrations2. Kassinin induces concentration-related contractions of the longitudinal muscle of the mouse distal colon.
Effect on endocrine pancreatic function - The effect of kassinin on endocrine pancreatic function was examined in the rat. Kassinin, injected intravenously in graded doses 10, 20, and 30 min before blood collection, significantly increased both plasma insulin and plasma glucagon in a dose-related fashion. The largest dose examined (10 µg) increased plasma insulin by 275% and plasma glucagon by 77% 7.
Synthetic kassinin affects splanchnic circulation - Effects of intravenously administered synthetic kassinin on splanchnic circulation and exocrine pancreatic secretion was examined in six anesthetized dogs. Kassinin caused dose-related increases in the blood flow in superior mesenteric artery and portal vein, and produced an initial increase followed by a decrease in pancreatic blood flow, but did not affect the exocrine pancreatic secretion. This study suggests that kassinin functions as a neuropeptide controlling the splanchnic circulation in mammalian species8.
References
1.Book : Handbook of chemical neuroanatomy. Chapter VI Neurokinin receptors in the CNS by Da-silva R, Mcleod AL, Krause JE.
2.Wang L, Zhou M, Lynch L, Chen T, Walker B, Shaw C (2009). Kassina senegalensis skin tachykinins: Molecular cloning of kassinin and (Thr2, Ile9)-kassinin biosynthetic precursor cDNAs and comparative bioactivity of mature tachykinins on the smooth muscle of rat urinary bladder. Biochimie, 91(5): 613-619.
3.Tan DP and Tsou K (1988). Differential Effects of Tachykinins Injected Intranigrally on Striatal Dopamine Metabolism. Journal of Neurochemistr, 51(5): 1333-1337.
4.Rani CR, Lynn AM, Cowsik SM (2001). Lipid Induced Conformation of the Tachykinin Peptide Kassinin. Journal of Biomolecular Structure and Dynamics, 18 (4): 611-625.
5.Lippe C, Bellantuon V, Ardizzone C, Cassano G (2004). Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin. Peptides, 25(11): 1971-1975.
6.Fontaine J and Lebrun P (1989). Contractile effects of substance P and other tachykinins on the mouse isolated distal colon. Br J Pharmacol, 96(3): 583–590.
7.Gullner HG, Yajimsa H, Harris V, Unger RH (1982). Kassinin: Stimulation of Insulin and Glucagon Secretion in the Rat. Endocrinology, 110 (4): 1246-1248.
8.Doi R, Inoue K, Kogire M, Sumi S, Takaori K, Yun M, Yajima H, Tobe T (1988). Effects of synthetic kassinin on splanchnic circulation and exocrine pancreas in dogs. Peptides, 9(5): 1055-1058.
Dodecapeptide tachykinin that is kassinin is found in the central nervous system of the amphibian Kassina senegalensis. It is similar in structure and action to other tachykinins, but it is especially effective in contracting smooth muscle tissue and stimulating the micturition reflex.
Discovery
In 1964, Erspamer et al., first demonstrated the occurrence of bioactive peptide, kassinin in amphibian skin1. A biosynthetic precursor of kassinin cDNA encoding the novel kassinin analog (Thr2, Ile9)-kassinin was identified in skin secretion of amphibian2. In 1983, two new mammalian tachykinins, neurokinin A and neurokinin B, were discovered in the porcine spinal cord. Their pharmacological actions more closely resemble those of the amphibian tachykinin kassinin and the molluscan tachykinin eledoisin3.
Structural Characteristics
Tachykinins are among the most widely-studied families of regulatory peptides characterized by a highly-conserved C-terminal -Phe-X-Gly-Leu-Met amide motif, which also constitutes the essential bioactive core. Both the aqueous and lipid-induced structure of kassinin, has been studied by Rani et al., (2001). Water kassinin prefers to be in an extended chain conformation, in the presence of perdeuterated dodecylphosphocholine (DPC) micelles, a membrane model system, helical conformation is induced in the central core and C-terminal region (K4-M12) of the peptide. N-terminus though less defined also displays some degree of order and a possible turn structure. The conformation adopted by kassinin in the presence of DPC micelles is consistent with the structural motif typical of neurokinin-1 selective agonists and with that reported for eledoisin in hydrophobic environment4.
Mode of Action
In frog skin, tachykinins stimulate the ion transport, by interacting with NK1-like receptors which can be estimated by measuring the short-circuit current (SCC) value. Kassinin (NK2 preferring in mammals) increases the SCC5. Kassinin also induces concentration-related contractions of the longitudinal muscle of the mouse distal colon. Contractile responses to the tachykinins result from a direct activation of smooth muscle cells. Kassinin evokes a contractile response in the absence of external Ca2+ and their myogenic activity was, to some extent, resistant to the inhibitory effect of nifedipine (a calcium channel blocker). So an additional process, probably the release of an intracellularly bound Ca2+ store, participates in the mechanism by which kassinin contracts the mouse distal colon. After desensitization of the mouse distal colon to Substance P (SP), the contractile activity provoked by SP was totally abolished whilst the responses evoked by kassinin were barely affected. These observations and other experimental findings indirectly support the assumption that the mouse distal colons possess different tachykinin-binding sites6.
Functions
Effect on rat urinary bladder - Synthetic replicates of kassinin are found to be active on rat urinary bladder smooth muscle at nanomolar concentrations2. Kassinin induces concentration-related contractions of the longitudinal muscle of the mouse distal colon.
Effect on endocrine pancreatic function - The effect of kassinin on endocrine pancreatic function was examined in the rat. Kassinin, injected intravenously in graded doses 10, 20, and 30 min before blood collection, significantly increased both plasma insulin and plasma glucagon in a dose-related fashion. The largest dose examined (10 µg) increased plasma insulin by 275% and plasma glucagon by 77% 7.
Synthetic kassinin affects splanchnic circulation - Effects of intravenously administered synthetic kassinin on splanchnic circulation and exocrine pancreatic secretion was examined in six anesthetized dogs. Kassinin caused dose-related increases in the blood flow in superior mesenteric artery and portal vein, and produced an initial increase followed by a decrease in pancreatic blood flow, but did not affect the exocrine pancreatic secretion. This study suggests that kassinin functions as a neuropeptide controlling the splanchnic circulation in mammalian species8.
References
1.Book : Handbook of chemical neuroanatomy. Chapter VI Neurokinin receptors in the CNS by Da-silva R, Mcleod AL, Krause JE.
2.Wang L, Zhou M, Lynch L, Chen T, Walker B, Shaw C (2009). Kassina senegalensis skin tachykinins: Molecular cloning of kassinin and (Thr2, Ile9)-kassinin biosynthetic precursor cDNAs and comparative bioactivity of mature tachykinins on the smooth muscle of rat urinary bladder. Biochimie, 91(5): 613-619.
3.Tan DP and Tsou K (1988). Differential Effects of Tachykinins Injected Intranigrally on Striatal Dopamine Metabolism. Journal of Neurochemistr, 51(5): 1333-1337.
4.Rani CR, Lynn AM, Cowsik SM (2001). Lipid Induced Conformation of the Tachykinin Peptide Kassinin. Journal of Biomolecular Structure and Dynamics, 18 (4): 611-625.
5.Lippe C, Bellantuon V, Ardizzone C, Cassano G (2004). Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin. Peptides, 25(11): 1971-1975.
6.Fontaine J and Lebrun P (1989). Contractile effects of substance P and other tachykinins on the mouse isolated distal colon. Br J Pharmacol, 96(3): 583–590.
7.Gullner HG, Yajimsa H, Harris V, Unger RH (1982). Kassinin: Stimulation of Insulin and Glucagon Secretion in the Rat. Endocrinology, 110 (4): 1246-1248.
8.Doi R, Inoue K, Kogire M, Sumi S, Takaori K, Yun M, Yajima H, Tobe T (1988). Effects of synthetic kassinin on splanchnic circulation and exocrine pancreas in dogs. Peptides, 9(5): 1055-1058.
Interleukins, Fragments and Related Peptides
Definition
The polypeptide hormone interleukin-1 (IL-1) is one of the key mediators of host's response to microbial invasion, inflammation, tissue injury, or immunological reactions. IL-1 is a prominent member of a group of polypeptide mediators now called cytokines.
Related Peptides
The IL-1 gene family is composed of IL-1a, IL-1b, and IL-1Ra. Each member is first synthesized as a precursor protein; the precursors for IL-1 (prolL-1a and prolL-1b) each have a molecular mass of 31 kDa. The prolL-1a and mature 17 kDa lL-1a are both biologically active. In contrast, prolL-1b is relatively inactive and requires cleavage to a 17-kDa peptide for optimal biological activity. The IL-1Ra precursor has a leader sequence, is cleaved to its mature form, and is secreted like most proteins1.
Structural Characteristics
IL-1 ligands (IL-1a and IL-1b, collectively referred to as IL-1) are pluripotent, proinflammatory cytokines. These two IL l’s share only small stretches of amino acid homology (26% in the case of human IL 1). Each IL 1 is coded by a separate gene, both genes are located on chromosome 2, and each gene contains seven exons. mRNA coding for IL-1b predominates over that coding for IL-1a and this prevalence of IL-1b has been observed in the proportion of the two IL 1 forms measured in the circulation and other body fluids. Both forms of IL 1 are unique in that they are initially translated as precursor polypeptides (31,000 kDa), and despite the fact that IL 1 is found in the extracellular compartment, neither form contains a signal cleavage sequence. The generation of the NH2 terminus of the mature peptide (17,500 kDa) and smaller peptides occurs by the action of senine proteases. Of particular interest is the a/b homologous region termed C-D, which is coded entirely by the sixth exon. It has been suggest that this region may contain the minimal recognition site for IL 1 receptors. Receptors for IL 1 equally recognize the b and a forms, both forms possess the same spectrum of biological properties, and molecular modeling studies reveal that the two IL l’s are composed of b - folded sheets2,3.
Mode of Action
IL 1 specifically binds to a variety of cells. Studies with T lymphocytes and fibroblasts suggest the existence of a single class of high-affinity receptor with a dissociation constant (KD) that varies from 5 to 50 pM with 100-4000 binding sites per cell. The high-affinity receptors are rapidly internalized and bind to nuclear structures, and responsiveness to IL 1 is down-regulated. The rapid down-regulation of IL 1 receptor is specific and may account, in part, for modulating IL1 effects in several cells4. In cells stimulated with IL1, cytosolic calcium increases, sodium/potassium ion fluxes occur, and protein kinase activity increases4.
Functions
Interleukin-1: Regulator of Neuroinflammation - Interleukins 1a and 1b (IL-1) are very potent signaling molecules that are expressed normally at low levels, but are induced rapidly in response to local or peripheral insults. IL-1 coordinates systemic host defense responses to pathogens and to injury within the central nervous system (CNS). Numerous reports have correlated the presence of IL-1 in the injured or diseased brain, and its effects on neurons and nonneuronal cells in the CNS, it has been recently shown that the importance of IL-1 signaling. Further it has been demonstrate that IL-1 is at or near the top of the hierarchical cytokine signaling cascade in the CNS that results in the activation of endogenous microglia and vascular endothelial cells to recruit peripheral leukocytes (i.e., neuroinflammation). The IL-1 system thus provides an attractive target for therapeutic intervention to ameliorate the destructive consequences of neuroinflammation5.
Role of interleukin-1 in stress responses - Stress responses have been characterized as central neurohormonal changes, as well as behavioral and physiological changes. Administration of IL-1 has been shown to induce effects comparable to stress-induced changes. IL-1 acts on the brain, especially the hypothalamus, to enhance release of monoamines, such as norepinephrine, dopamine, and serotonin, as well as secretion of corticotropin-releasing hormone (CRH). IL-1-induced activation of the hypothalamo-pituitary-adrenal (HPA) axis in vivo depends on secretion of CRH, an intact pituitary, and the ventral noradrenergic bundle that innervates the CRH-containing neurons in the paraventricular nucleus of the hypothalamus. Recent studies have shown that IL-1 is present within neurons in the brain, suggesting that IL-1 functions in neuronal transmission. It has been shown that IL-1 in the brain is involved in the stress response, and that stress-induced activation of monoamine release and the HPA axis were inhibited by IL-1 receptor antagonist (IL-1Ra) administration directly into the rat hypothalamus. IL-1Ra has been known to exert a blocking effect on IL-1 by competitively inhibiting the binding of IL-1 to IL-1 receptors6.
References
1.Dinarello CA (1994). The interleukin-1 family. 10 years of discovery. FASEBJ, 8(15):1314-25.
2.Auron PE, Warner SJ, Webb AC, Cannon JG, Bernheim HA, McAdam KJ, Rosenwasser LJ, LoPreste G, Mucci SF, Dinarello CA (1987). Studies on the molecular nature of human interleukin-1. J. Immunol, 138(5):1447-1456.
3.Dinarello C A (1988). Biology of interleukin 1. FASEBJ, 2: 108-115.
4.Mizel S B, Kilian P L, Lewis J C, Paganelli KA, Chizzonite RA (1987). The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J. Immunol., 138: 2906-2912.
5.Basu A, Krady JK, Levison SW(2004). Interleukin-1: A Master Regulator of Neuroinflammation. Journal of Neuroscience Research, 78:151–156.
6.Shintani F, Nakaki T, Kanba S, Kato R, Asai M(1995). Role of interleukin-1 in stress responses - A putative neurotransmitter. Molecular Neurobiology, 10: 47-71.
The polypeptide hormone interleukin-1 (IL-1) is one of the key mediators of host's response to microbial invasion, inflammation, tissue injury, or immunological reactions. IL-1 is a prominent member of a group of polypeptide mediators now called cytokines.
Related Peptides
The IL-1 gene family is composed of IL-1a, IL-1b, and IL-1Ra. Each member is first synthesized as a precursor protein; the precursors for IL-1 (prolL-1a and prolL-1b) each have a molecular mass of 31 kDa. The prolL-1a and mature 17 kDa lL-1a are both biologically active. In contrast, prolL-1b is relatively inactive and requires cleavage to a 17-kDa peptide for optimal biological activity. The IL-1Ra precursor has a leader sequence, is cleaved to its mature form, and is secreted like most proteins1.
Structural Characteristics
IL-1 ligands (IL-1a and IL-1b, collectively referred to as IL-1) are pluripotent, proinflammatory cytokines. These two IL l’s share only small stretches of amino acid homology (26% in the case of human IL 1). Each IL 1 is coded by a separate gene, both genes are located on chromosome 2, and each gene contains seven exons. mRNA coding for IL-1b predominates over that coding for IL-1a and this prevalence of IL-1b has been observed in the proportion of the two IL 1 forms measured in the circulation and other body fluids. Both forms of IL 1 are unique in that they are initially translated as precursor polypeptides (31,000 kDa), and despite the fact that IL 1 is found in the extracellular compartment, neither form contains a signal cleavage sequence. The generation of the NH2 terminus of the mature peptide (17,500 kDa) and smaller peptides occurs by the action of senine proteases. Of particular interest is the a/b homologous region termed C-D, which is coded entirely by the sixth exon. It has been suggest that this region may contain the minimal recognition site for IL 1 receptors. Receptors for IL 1 equally recognize the b and a forms, both forms possess the same spectrum of biological properties, and molecular modeling studies reveal that the two IL l’s are composed of b - folded sheets2,3.
Mode of Action
IL 1 specifically binds to a variety of cells. Studies with T lymphocytes and fibroblasts suggest the existence of a single class of high-affinity receptor with a dissociation constant (KD) that varies from 5 to 50 pM with 100-4000 binding sites per cell. The high-affinity receptors are rapidly internalized and bind to nuclear structures, and responsiveness to IL 1 is down-regulated. The rapid down-regulation of IL 1 receptor is specific and may account, in part, for modulating IL1 effects in several cells4. In cells stimulated with IL1, cytosolic calcium increases, sodium/potassium ion fluxes occur, and protein kinase activity increases4.
Functions
Interleukin-1: Regulator of Neuroinflammation - Interleukins 1a and 1b (IL-1) are very potent signaling molecules that are expressed normally at low levels, but are induced rapidly in response to local or peripheral insults. IL-1 coordinates systemic host defense responses to pathogens and to injury within the central nervous system (CNS). Numerous reports have correlated the presence of IL-1 in the injured or diseased brain, and its effects on neurons and nonneuronal cells in the CNS, it has been recently shown that the importance of IL-1 signaling. Further it has been demonstrate that IL-1 is at or near the top of the hierarchical cytokine signaling cascade in the CNS that results in the activation of endogenous microglia and vascular endothelial cells to recruit peripheral leukocytes (i.e., neuroinflammation). The IL-1 system thus provides an attractive target for therapeutic intervention to ameliorate the destructive consequences of neuroinflammation5.
Role of interleukin-1 in stress responses - Stress responses have been characterized as central neurohormonal changes, as well as behavioral and physiological changes. Administration of IL-1 has been shown to induce effects comparable to stress-induced changes. IL-1 acts on the brain, especially the hypothalamus, to enhance release of monoamines, such as norepinephrine, dopamine, and serotonin, as well as secretion of corticotropin-releasing hormone (CRH). IL-1-induced activation of the hypothalamo-pituitary-adrenal (HPA) axis in vivo depends on secretion of CRH, an intact pituitary, and the ventral noradrenergic bundle that innervates the CRH-containing neurons in the paraventricular nucleus of the hypothalamus. Recent studies have shown that IL-1 is present within neurons in the brain, suggesting that IL-1 functions in neuronal transmission. It has been shown that IL-1 in the brain is involved in the stress response, and that stress-induced activation of monoamine release and the HPA axis were inhibited by IL-1 receptor antagonist (IL-1Ra) administration directly into the rat hypothalamus. IL-1Ra has been known to exert a blocking effect on IL-1 by competitively inhibiting the binding of IL-1 to IL-1 receptors6.
References
1.Dinarello CA (1994). The interleukin-1 family. 10 years of discovery. FASEBJ, 8(15):1314-25.
2.Auron PE, Warner SJ, Webb AC, Cannon JG, Bernheim HA, McAdam KJ, Rosenwasser LJ, LoPreste G, Mucci SF, Dinarello CA (1987). Studies on the molecular nature of human interleukin-1. J. Immunol, 138(5):1447-1456.
3.Dinarello C A (1988). Biology of interleukin 1. FASEBJ, 2: 108-115.
4.Mizel S B, Kilian P L, Lewis J C, Paganelli KA, Chizzonite RA (1987). The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J. Immunol., 138: 2906-2912.
5.Basu A, Krady JK, Levison SW(2004). Interleukin-1: A Master Regulator of Neuroinflammation. Journal of Neuroscience Research, 78:151–156.
6.Shintani F, Nakaki T, Kanba S, Kato R, Asai M(1995). Role of interleukin-1 in stress responses - A putative neurotransmitter. Molecular Neurobiology, 10: 47-71.
Insulin-Like Growth Factors (IGF), Fragments and Related Peptides
Definition
Insulin-like growth factors (IGF)-1 and IGF-2 are ubiquitously expressed peptides with sequence homology to insulin.
Related Peptides
IGFs interacts with a specific receptor on the cell membrane, namely, the IGF-I receptor (IGF-IR), and the interaction is regulated by a group of specific binding proteins. All of these molecules are considered to be members of the IGF family, which includes the polypeptide ligands IGF-I and IGF-II, two types of cell membrane receptors (i.e., IGF-IR and IGF-IIR), and six IGF-binding proteins (i.e., IGFBP-1 through IGFBP-6).
Structural Characteristics
IGFs
IGF-I and IGF-II are single-chain polypeptides. The two molecules have 62% homology in their amino acid sequences. The molecules share additional structural similarities, and their structures resemble the structure of proinsulin1. IGF I consists of 70 amino acid residues, IGF I1 of 67, grouped into domains A and B (similar to insulin), C (analogous to the connecting peptide of proinsulin) and D (not present in insulins). The three intrachain disulfide bridges in IGF 1 and I1 have shown to be located in analogous positions to those in (pro) insulin1.
IGFBPs
The primary structures of mammalian IGFBPs appear to contain three distinct domains of roughly equivalent sizes: the conserved N-terminal domain, the highly variable midregion, and the conserved C-terminal domain.N-terminal domain contains 80–93 amino acid residues after the signal. Ten to 12 of the 16–20 cysteines found in the prepeptides are located within this domain. In IGFBP-1 to -5, these 12 cysteines are fully conserved, whereas in IGFBP-6, 10 of the 12 cysteines are invariant2.Midregion ranging in size from 55 amino acid residues to 95 amino acids separates the N-terminal domain from the C-terminal domain. The amino acid sequence for each midsegment appears to be unique to the protein. C-terminal region are highly conserved and, 6 cysteines of the total 16–20 cysteines are found in the C terminus and are strictly conserved2.
IGF Receptors
Both IGF-IR and IGF-IIR are glycoproteins and are located on the cell membrane. IGF-IR is a tetramer of two identical a-subunits and two identical ß-subunits. Structurally, IGF-IR resembles the insulin receptor, and there is 60% homology between them. IGF-IIR is monomeric. Three ligand-binding regions are found in the extracellular domain of the receptor, one for IGF-II binding and two for proteins containing mannose-6-phosphate (M6P), including renin, proliferin, thyroglobulin, and the latent form of (TGF)-ß transforming growth factor2.
Mode of Action
Binding of IGFs to IGF-IR activates the receptor's tyrosine kinase activity, which triggers a cascade of reactions. Two distinct signal transduction pathways have been identified for IGF-IR. One pathway activates Ras protein, Raf protein, and mitogen-activated protein kinase, and the other pathway involves phosphoinositol-3-kinase. IGF-IR is involved in cell transformation. In vitro experiments have shown that removal of IGF-IR from the cell membrane by eliminating the IGF-IR gene, by suppressing its expression, or by inhibiting its function can abolish cell transformation3. IGFBPs have multiple and complex functions. IGFBPs are able to inhibit or to enhance the action of IGFs, resulting in either suppression or stimulation of cell proliferation. These opposing effects of IGFBPs on IGFs are determined by the molecular structures of the binding proteins. When binding to IGFs, IGFBPs play three major roles: 1) transporting IGFs, 2) protecting IGFs from degradation, and 3) regulating the interaction between IGFs and IGF-IR. Normally, IGFBPs have higher binding affinity to IGFs than does IGF-IR; therefore, binding of IGFBPs to IGFs blocks the interaction between IGFs and IGF-IR and suppresses IGF action. However, binding of IGFBPs to IGFs also protects IGFs from proteolytic degradation, and that protection can enhance the action of IGFs by increasing their bioavailability in local tissue3.
Functions
Direct Involvement in Cancer - IGF-I and IGF-II are strong mitogens for a wide variety of cancer cell lines. Animal experiments indicate that overexpression of IGF-I increase the likelihood of tumor development in certain tissues. The effects of IGFs on cancer cells are mediated through IGF-IR. Eliminating IGF-IR from the cell membrane, blocking the interaction of IGFs with IGF-IR, or interrupting the signal transduction pathway of IGF-IR can abolish the mitogenic action of IGFs on cancer cells. IGF-IR is overexpressed in certain cancers, and its overexpression is associated with aggressive tumors. A recent study indicates that the insulin receptor is involved in mediating the actions of IGF-II on breast cancer. Cancer cells with a strong tendency to metastasize have higher expression of IGF-II and IGF-IR than those with a low ability to do so.In cancer, IGFBPs regulate the action of IGFs. In most situations, the binding proteins suppress the mitogenic action of IGFs and promote apoptosis. It has been shown that IGFBP-3 inhibited breast cancer cell growth without interacting with IGFs4.
IGF I protects and rescues hippocampal neurons against ß-amyloid- and human amylin-induced toxicity - Insulin-like growth factors (IGF-I and IGF-II) are well known trophic factors and their specific receptors are uniquely distributed throughout the brain, being especially concentrated in the hippocampal formation. IGFs possess neurotrophic activities in the hippocampus, an area severely affected in Alzheimer disease. There is evidence that ß-amyloid (aß)-derived peptides likely play an important role in the neurodegenerative process observed in Alzheimer disease, it has been shown that IGFs can be neuroprotective to hippocampal neurons against toxicity induced by amyloidogenic derivatives5.
Reference:
1.Daughaday WH, Rotwein P (1989). Insulin-like growth factors I and II - Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev, 10:68–91.
2.Jones JI, Clemmons DR (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16:3–34.
3.Clemmons DR (1997). Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev, 8:45–62.
4.Yu H, Rohan T (2000). Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression. Journal of the National Cancer Institute., 92 (18):1472-1489.
5.Doré S, Kar S, Quirion R (1997). Insulin-like growth factor I protects and rescues hippocampal neurons against ß-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci, 94:4772–4777.
Insulin-like growth factors (IGF)-1 and IGF-2 are ubiquitously expressed peptides with sequence homology to insulin.
Related Peptides
IGFs interacts with a specific receptor on the cell membrane, namely, the IGF-I receptor (IGF-IR), and the interaction is regulated by a group of specific binding proteins. All of these molecules are considered to be members of the IGF family, which includes the polypeptide ligands IGF-I and IGF-II, two types of cell membrane receptors (i.e., IGF-IR and IGF-IIR), and six IGF-binding proteins (i.e., IGFBP-1 through IGFBP-6).
Structural Characteristics
IGFs
IGF-I and IGF-II are single-chain polypeptides. The two molecules have 62% homology in their amino acid sequences. The molecules share additional structural similarities, and their structures resemble the structure of proinsulin1. IGF I consists of 70 amino acid residues, IGF I1 of 67, grouped into domains A and B (similar to insulin), C (analogous to the connecting peptide of proinsulin) and D (not present in insulins). The three intrachain disulfide bridges in IGF 1 and I1 have shown to be located in analogous positions to those in (pro) insulin1.
IGFBPs
The primary structures of mammalian IGFBPs appear to contain three distinct domains of roughly equivalent sizes: the conserved N-terminal domain, the highly variable midregion, and the conserved C-terminal domain.N-terminal domain contains 80–93 amino acid residues after the signal. Ten to 12 of the 16–20 cysteines found in the prepeptides are located within this domain. In IGFBP-1 to -5, these 12 cysteines are fully conserved, whereas in IGFBP-6, 10 of the 12 cysteines are invariant2.Midregion ranging in size from 55 amino acid residues to 95 amino acids separates the N-terminal domain from the C-terminal domain. The amino acid sequence for each midsegment appears to be unique to the protein. C-terminal region are highly conserved and, 6 cysteines of the total 16–20 cysteines are found in the C terminus and are strictly conserved2.
IGF Receptors
Both IGF-IR and IGF-IIR are glycoproteins and are located on the cell membrane. IGF-IR is a tetramer of two identical a-subunits and two identical ß-subunits. Structurally, IGF-IR resembles the insulin receptor, and there is 60% homology between them. IGF-IIR is monomeric. Three ligand-binding regions are found in the extracellular domain of the receptor, one for IGF-II binding and two for proteins containing mannose-6-phosphate (M6P), including renin, proliferin, thyroglobulin, and the latent form of (TGF)-ß transforming growth factor2.
Mode of Action
Binding of IGFs to IGF-IR activates the receptor's tyrosine kinase activity, which triggers a cascade of reactions. Two distinct signal transduction pathways have been identified for IGF-IR. One pathway activates Ras protein, Raf protein, and mitogen-activated protein kinase, and the other pathway involves phosphoinositol-3-kinase. IGF-IR is involved in cell transformation. In vitro experiments have shown that removal of IGF-IR from the cell membrane by eliminating the IGF-IR gene, by suppressing its expression, or by inhibiting its function can abolish cell transformation3. IGFBPs have multiple and complex functions. IGFBPs are able to inhibit or to enhance the action of IGFs, resulting in either suppression or stimulation of cell proliferation. These opposing effects of IGFBPs on IGFs are determined by the molecular structures of the binding proteins. When binding to IGFs, IGFBPs play three major roles: 1) transporting IGFs, 2) protecting IGFs from degradation, and 3) regulating the interaction between IGFs and IGF-IR. Normally, IGFBPs have higher binding affinity to IGFs than does IGF-IR; therefore, binding of IGFBPs to IGFs blocks the interaction between IGFs and IGF-IR and suppresses IGF action. However, binding of IGFBPs to IGFs also protects IGFs from proteolytic degradation, and that protection can enhance the action of IGFs by increasing their bioavailability in local tissue3.
Functions
Direct Involvement in Cancer - IGF-I and IGF-II are strong mitogens for a wide variety of cancer cell lines. Animal experiments indicate that overexpression of IGF-I increase the likelihood of tumor development in certain tissues. The effects of IGFs on cancer cells are mediated through IGF-IR. Eliminating IGF-IR from the cell membrane, blocking the interaction of IGFs with IGF-IR, or interrupting the signal transduction pathway of IGF-IR can abolish the mitogenic action of IGFs on cancer cells. IGF-IR is overexpressed in certain cancers, and its overexpression is associated with aggressive tumors. A recent study indicates that the insulin receptor is involved in mediating the actions of IGF-II on breast cancer. Cancer cells with a strong tendency to metastasize have higher expression of IGF-II and IGF-IR than those with a low ability to do so.In cancer, IGFBPs regulate the action of IGFs. In most situations, the binding proteins suppress the mitogenic action of IGFs and promote apoptosis. It has been shown that IGFBP-3 inhibited breast cancer cell growth without interacting with IGFs4.
IGF I protects and rescues hippocampal neurons against ß-amyloid- and human amylin-induced toxicity - Insulin-like growth factors (IGF-I and IGF-II) are well known trophic factors and their specific receptors are uniquely distributed throughout the brain, being especially concentrated in the hippocampal formation. IGFs possess neurotrophic activities in the hippocampus, an area severely affected in Alzheimer disease. There is evidence that ß-amyloid (aß)-derived peptides likely play an important role in the neurodegenerative process observed in Alzheimer disease, it has been shown that IGFs can be neuroprotective to hippocampal neurons against toxicity induced by amyloidogenic derivatives5.
Reference:
1.Daughaday WH, Rotwein P (1989). Insulin-like growth factors I and II - Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev, 10:68–91.
2.Jones JI, Clemmons DR (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16:3–34.
3.Clemmons DR (1997). Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev, 8:45–62.
4.Yu H, Rohan T (2000). Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression. Journal of the National Cancer Institute., 92 (18):1472-1489.
5.Doré S, Kar S, Quirion R (1997). Insulin-like growth factor I protects and rescues hippocampal neurons against ß-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci, 94:4772–4777.
Inhibitors of FTase, GGTase
Definition
Farnesyltransferase inhibitors (FTIs) are a group of drugs that selectively inhibit the enzyme farnesyltransferase (FTase) that is responsible for the transfer of a farnesyl group to Ras and other proteins involved in signaling concerning cell transformation and survival.
Geranylgeranyl transferase type 1 inhibitor can affect critical cellular processes such as inhibition of platelet-derived growth factor receptor tyrosine kinase phosphorylation and growth arrest of human neoplastic cells in G1, presumably through inhibition of RhoA geranylgeranylation.
Methyltransferase inhibitors have ability to inhibit hypermethylation, restore suppressor gene expression and exert antitumor effects.
Structural Characteristics
Farnesyl protein transferase inhibitors - Initial approaches to FT inhibition involved the use of general inhibitors of isoprenylation. Synthesis of farnesyl groups can be blocked by the HMG CoA (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as lovastatin, and the mevalonate pyrophosphate decarboxylase inhibitor phenylacetate1.
The FTIs fall into three main classes: 1) the CAAX competitive inhibitors, 2) the FPP competitive inhibitors and 3) the bisubstrate inhibitors.
Peptidomimetic GGTIs have been described. These include aminobenzoic acid derivatives such as GGTI-298 and GGTI-2154 and benzoyleneurea-based compounds. Studies with these compounds have revealed a number of consequences of cellular exposure to a GGTI. Administration of GGTI to cells can cause cell cycle arrest at G0/G1, and this effect appears to be mediated by inactivation of CDK2/4 through the p21/p15 kinase inhibitors downstream of Rho. GGTIs are also potent stimulators of apoptosis in both normal and transformed cell lines2, 3.
DNA methyltransferase inhibitors - DNA methylation inhibitors have demonstrated the ability to inhibit hypermethylation, restore suppressor gene expression and exert antitumor effects. Four inhibitors, which are analogs of the nucleoside deoxycitidine, have been clinically tested: 5-azacytidine, 5-aza-2'-deoxycytidine, 1-ß-D-arabinofuranosyl-5-azacytosine and dihydro-5-azacytidine. The first two have demonstrated encouraging antileukemic activity but little activity in solid tumors, while the latter two are no longer under study due to lack of efficacy4.
Mode of Action
Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome - In a study, using breast tumor models, it has been shown those agents possessing a lactone moiety, including statins (such as lovastatin) and the isoprenoid inhibitors (such as FTI-277 and GGTI-298), mediate their cell cycle inhibitory activities by blocking the chymotrypsin activity of the proteasome. This results in the accumulation of cyclin-dependent kinase inhibitors p21 and p27 with subsequent G1 arrest. Cells devoid of p21 were refractory to the growth-inhibitory activity of lovastatin, FTI-277, and GGTI-298. However, in p21 null cells, isoprenylation of key substrates of farnesyl transferase (such as Ras) and of geranylgeranyl transferase (such as RAP-1) were inhibited by FTI-277 and GGTI-298, respectively, suggesting that although both these isoprenoid inhibitors reached and inhibited their intended targets, inhibition of the isoprenylation of Ras and RAP-1A are not sufficient to mediate G1 arrest5.
DNA methyltransferase inhibitors - These drugs act by preventing methylation. Decitabine, for example, when incorporated into DNA, covalently link with DNMT which may induce cell death by obstructing DNA synthesis. They may also induce DNA damage through structural instability at the site of incorporation6.
Functions
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression – it has been demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs7.
DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells - In a study, 5-azacytidine, a DNA methyltransferase inhibitor showed significant cytotoxicity against both conventional therapy-sensitive and therapy-resistant MM cell lines, as well as multidrug-resistant patient-derived MM cells, with IC50 of 0.8–3 µmol/L. Conversely, 5-azacytidine was not cytotoxic to peripheral blood mononuclear cells or patient-derived bone marrow stromal cells (BMSC) at these doses. 5-Azacytidine treatment induced DNA double-strand break (DSB) responses, as evidenced by H2AX, Chk2, and p53 phosphorylations, and apoptosis of MM cells. Further it has been shown that 5-azacytidine–induced DNA DSB responses were mediated predominantly by ATR, and that doxorubicin, as well as bortezomib, synergistically enhanced 5-azacytidine–induced MM cell death8.
References:
1.End DW (1999). Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New. Drugs, 17:241–258.
2.Lerner EC, Qian Y, Hamilton AD, Sebti SM (1995). Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltranferase I inhibitor. J. Biol. Chem, 270:26770–26773.
3.Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD (1995). Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem, 42:1333–1340.
4.Goffin J, Eisenhauer E (2002). DNA methyltransferase inhibitors—state of the art. Annals of Oncology, 13:1699-1716.
5.Efuet ET, Keyomarsi K (2006). Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. Cancer Research, 66(2): 1040-1051.
6.Juttermann R, Li E, Jaenisch R (1994). Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci, 91(25): 11797–11801.
7.Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, Chellappan S, Sebti SM (2006). Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene, 1;26(5):633-40.
8.Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC (2007). 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol. Cancer. Ther. 6(6):1718–1727.
Farnesyltransferase inhibitors (FTIs) are a group of drugs that selectively inhibit the enzyme farnesyltransferase (FTase) that is responsible for the transfer of a farnesyl group to Ras and other proteins involved in signaling concerning cell transformation and survival.
Geranylgeranyl transferase type 1 inhibitor can affect critical cellular processes such as inhibition of platelet-derived growth factor receptor tyrosine kinase phosphorylation and growth arrest of human neoplastic cells in G1, presumably through inhibition of RhoA geranylgeranylation.
Methyltransferase inhibitors have ability to inhibit hypermethylation, restore suppressor gene expression and exert antitumor effects.
Structural Characteristics
Farnesyl protein transferase inhibitors - Initial approaches to FT inhibition involved the use of general inhibitors of isoprenylation. Synthesis of farnesyl groups can be blocked by the HMG CoA (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as lovastatin, and the mevalonate pyrophosphate decarboxylase inhibitor phenylacetate1.
The FTIs fall into three main classes: 1) the CAAX competitive inhibitors, 2) the FPP competitive inhibitors and 3) the bisubstrate inhibitors.
Peptidomimetic GGTIs have been described. These include aminobenzoic acid derivatives such as GGTI-298 and GGTI-2154 and benzoyleneurea-based compounds. Studies with these compounds have revealed a number of consequences of cellular exposure to a GGTI. Administration of GGTI to cells can cause cell cycle arrest at G0/G1, and this effect appears to be mediated by inactivation of CDK2/4 through the p21/p15 kinase inhibitors downstream of Rho. GGTIs are also potent stimulators of apoptosis in both normal and transformed cell lines2, 3.
DNA methyltransferase inhibitors - DNA methylation inhibitors have demonstrated the ability to inhibit hypermethylation, restore suppressor gene expression and exert antitumor effects. Four inhibitors, which are analogs of the nucleoside deoxycitidine, have been clinically tested: 5-azacytidine, 5-aza-2'-deoxycytidine, 1-ß-D-arabinofuranosyl-5-azacytosine and dihydro-5-azacytidine. The first two have demonstrated encouraging antileukemic activity but little activity in solid tumors, while the latter two are no longer under study due to lack of efficacy4.
Mode of Action
Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome - In a study, using breast tumor models, it has been shown those agents possessing a lactone moiety, including statins (such as lovastatin) and the isoprenoid inhibitors (such as FTI-277 and GGTI-298), mediate their cell cycle inhibitory activities by blocking the chymotrypsin activity of the proteasome. This results in the accumulation of cyclin-dependent kinase inhibitors p21 and p27 with subsequent G1 arrest. Cells devoid of p21 were refractory to the growth-inhibitory activity of lovastatin, FTI-277, and GGTI-298. However, in p21 null cells, isoprenylation of key substrates of farnesyl transferase (such as Ras) and of geranylgeranyl transferase (such as RAP-1) were inhibited by FTI-277 and GGTI-298, respectively, suggesting that although both these isoprenoid inhibitors reached and inhibited their intended targets, inhibition of the isoprenylation of Ras and RAP-1A are not sufficient to mediate G1 arrest5.
DNA methyltransferase inhibitors - These drugs act by preventing methylation. Decitabine, for example, when incorporated into DNA, covalently link with DNMT which may induce cell death by obstructing DNA synthesis. They may also induce DNA damage through structural instability at the site of incorporation6.
Functions
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression – it has been demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs7.
DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells - In a study, 5-azacytidine, a DNA methyltransferase inhibitor showed significant cytotoxicity against both conventional therapy-sensitive and therapy-resistant MM cell lines, as well as multidrug-resistant patient-derived MM cells, with IC50 of 0.8–3 µmol/L. Conversely, 5-azacytidine was not cytotoxic to peripheral blood mononuclear cells or patient-derived bone marrow stromal cells (BMSC) at these doses. 5-Azacytidine treatment induced DNA double-strand break (DSB) responses, as evidenced by H2AX, Chk2, and p53 phosphorylations, and apoptosis of MM cells. Further it has been shown that 5-azacytidine–induced DNA DSB responses were mediated predominantly by ATR, and that doxorubicin, as well as bortezomib, synergistically enhanced 5-azacytidine–induced MM cell death8.
References:
1.End DW (1999). Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New. Drugs, 17:241–258.
2.Lerner EC, Qian Y, Hamilton AD, Sebti SM (1995). Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltranferase I inhibitor. J. Biol. Chem, 270:26770–26773.
3.Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD (1995). Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem, 42:1333–1340.
4.Goffin J, Eisenhauer E (2002). DNA methyltransferase inhibitors—state of the art. Annals of Oncology, 13:1699-1716.
5.Efuet ET, Keyomarsi K (2006). Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. Cancer Research, 66(2): 1040-1051.
6.Juttermann R, Li E, Jaenisch R (1994). Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci, 91(25): 11797–11801.
7.Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, Chellappan S, Sebti SM (2006). Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene, 1;26(5):633-40.
8.Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC (2007). 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol. Cancer. Ther. 6(6):1718–1727.
Hydrins
Definition
Hydrins 1 and 2 have been isolated from the pituitary glands of Xenopus laevis and Rana esculenta, respectively. It is assumed that the hydrins could be involved in the water-electrolyte regulation of amphibians.
Discovery
Earlier reports show that neurohypophysial extracts of anurans contain a third class of peptides. Isolation of neurohypophysial peptides by high pressure liquid chromatography (HPLC) from a number of anuran Amphibia has revealed the presence of peptides that is not detected in other non-mammalian tetrapods. These peptides were sequenced and named “hydrins” in 1989.
Structural Characteristics
Hydrins seem to be derived from the pro-vasotocin-neurophysin precursor. The differential maturation of provasotocin leads to processing-arrested intermediates, namely vasotocinyl-Gly (Hydrin 2) in virtually all anuran amphibians and vasotocinyl-Gly-Lys-Arg (Hydrin 1) in Xenopus laevis. These intermediates result from a down regulation of the alpha-amidating enzyme or carboxypeptidase E, respectively. Hydrins, in contrast to vasotocin, are not active on rat uterus or rat blood pressure. They are absent from other vasotocin bearers such as birds and could be involved specifically in water-electrolyte regulation of amphibians1.
Mode of Action
Distinct hydroosmotic receptors for the neurohypophyseal peptides vasotocin and Hydrins: A comparative study was conducted to examine the biological properties of vasotocin, hydrin 1 (vasotocinyl-Gly-Lys-Arg) and hydrin 2 (vasotocinyl-Gly), in particular the hydro-osmotic activities on the frog skin, the frog urinary bladder and the frog kidney. It has been shown that Hydrins are as active as or more active than vasotocin on the first two organs but they are virtually devoid of antidiuretic activity in the rat and the frog, in contrast to vasotocin. Further, it appears that where the oxytocin ring (residues 1-6), present in the three peptides, is necessary for the action on the three organs, the C-terminal amidated group of vasotocin is necessary for the renal receptor but not for the skin and bladder receptors. It has been suggested that adaptation has led to specialization of (at least) two subtypes of hydro-osmotic V2 receptors, the renal subtype on which vasotocin is mainly active for the reabsorption of tubular water, and the skin/bladder subtype on which hydrin 2 is specifically involved in ensuring the rehydration of the animal2.
Functions
Effects of hydrin2 on cutaneous electrical properties of Rana pipiens -
In a study, electrical properties were measured in isolated skin patches from leopard frogs (Rana pipiens) to explore the possibility that hydrin 2 (vasotocinyl-gly) may regulate cutaneous ion transport. Hydrin 2 is a neurohypophysial peptide commonly implicated in rehydration of anurans. Experimental frogs were given either one or two intraperitoneal (i.p.) injections of hydrin 2 in saline solution, each calculated to achieve a final blood concentration of 81 ng/ml. After a 2-h equilibration period, the frogs were euthanized and abdominal skin removed and used for study. Results of this study confirm that exposure of R. pipiens to hydrin 2 promotes a highly significant increase in transepithelial potential (TEP) and short-circuit current (Isc).In a dose–response study, 10-fold increases in serosal hydrin 2 concentration triggered significant changes in TEP and Isc, with maximal responses observed at 10 ng/ml. Because hydrin 2 is known to facilitate “cutaneous drinking” in anurans, this study suggests a correlation between ion and water transport across the skin3.
A fluorescent analogue of hydrin 1: a new probe for vasotocin receptors - In a study, deamino and fluorescein analogues of hydrin 1 were used to characterize their physiological action in the urinary bladder of the toad, Bufo marinus. It was shown that 1-Deamino-hydrin 1 (d-hydrin) was more potent than vasotocin in stimulating osmotic water flow across intact bladders and more potent than vasotocin in displacing tritium-labeled vasopressin [(3H] AVP) from cell membranes. Furthermore, 1-Deamino-[11-lysine (fluorescein)]-hydrin 1 (flu-hydrin) was found to be the most potent fluorescent vasotocin receptor probe synthesized to date. Flu-hydrin increased osmotic water flow across bladders with a half-maximal effective dose (ED50) value of 6 x 10(-10) M and displaced [3H]AVP from membranes with a half-maximal concentration (IC50) value of 3 x 10(-9) M. This study shows that d-hydrin can serve as a foundation molecule to which reporter groups, such as fluorescent residues, can be attached with better preservation of hydrosmotic activity than is possible with similar modifications of vasotocin4.
References
1.Rouille Y, Michel G, Chauvet MT, Chauvet J, Acher R (1989). Hydrins, hydroosmotic neurohypophyseal peptides osmoregulatory adaptation in amphibians through vasotocin precursor processing. Proc. Natl. Acad. Sci, 86:5272–5275.
2.Rouille Y, Ouedraogo Y, Chauvet J, Acher R (1995). Distinct hydroosmotic receptors for the neurohypophyseal peptides vasotocin and hydrins in the frog Rana esculenta. Neuropeptides, 29:301–307.
3.Ford NA, Robinson GD (2003). Effects of hydrin 2 on cutaneous electrical properties of Rana pipiens. General and Comparative Endocrinology, 134 (2):103-108.
4.Eggena P, Ma CL, Lu MQ, Buku A (1990). A fluorescent analogue of hydrin 1: a new probe for vasotocin receptors. Am J Physiol Endocrinol Metab, 259:524-528.
Hydrins 1 and 2 have been isolated from the pituitary glands of Xenopus laevis and Rana esculenta, respectively. It is assumed that the hydrins could be involved in the water-electrolyte regulation of amphibians.
Discovery
Earlier reports show that neurohypophysial extracts of anurans contain a third class of peptides. Isolation of neurohypophysial peptides by high pressure liquid chromatography (HPLC) from a number of anuran Amphibia has revealed the presence of peptides that is not detected in other non-mammalian tetrapods. These peptides were sequenced and named “hydrins” in 1989.
Structural Characteristics
Hydrins seem to be derived from the pro-vasotocin-neurophysin precursor. The differential maturation of provasotocin leads to processing-arrested intermediates, namely vasotocinyl-Gly (Hydrin 2) in virtually all anuran amphibians and vasotocinyl-Gly-Lys-Arg (Hydrin 1) in Xenopus laevis. These intermediates result from a down regulation of the alpha-amidating enzyme or carboxypeptidase E, respectively. Hydrins, in contrast to vasotocin, are not active on rat uterus or rat blood pressure. They are absent from other vasotocin bearers such as birds and could be involved specifically in water-electrolyte regulation of amphibians1.
Mode of Action
Distinct hydroosmotic receptors for the neurohypophyseal peptides vasotocin and Hydrins: A comparative study was conducted to examine the biological properties of vasotocin, hydrin 1 (vasotocinyl-Gly-Lys-Arg) and hydrin 2 (vasotocinyl-Gly), in particular the hydro-osmotic activities on the frog skin, the frog urinary bladder and the frog kidney. It has been shown that Hydrins are as active as or more active than vasotocin on the first two organs but they are virtually devoid of antidiuretic activity in the rat and the frog, in contrast to vasotocin. Further, it appears that where the oxytocin ring (residues 1-6), present in the three peptides, is necessary for the action on the three organs, the C-terminal amidated group of vasotocin is necessary for the renal receptor but not for the skin and bladder receptors. It has been suggested that adaptation has led to specialization of (at least) two subtypes of hydro-osmotic V2 receptors, the renal subtype on which vasotocin is mainly active for the reabsorption of tubular water, and the skin/bladder subtype on which hydrin 2 is specifically involved in ensuring the rehydration of the animal2.
Functions
Effects of hydrin2 on cutaneous electrical properties of Rana pipiens -
In a study, electrical properties were measured in isolated skin patches from leopard frogs (Rana pipiens) to explore the possibility that hydrin 2 (vasotocinyl-gly) may regulate cutaneous ion transport. Hydrin 2 is a neurohypophysial peptide commonly implicated in rehydration of anurans. Experimental frogs were given either one or two intraperitoneal (i.p.) injections of hydrin 2 in saline solution, each calculated to achieve a final blood concentration of 81 ng/ml. After a 2-h equilibration period, the frogs were euthanized and abdominal skin removed and used for study. Results of this study confirm that exposure of R. pipiens to hydrin 2 promotes a highly significant increase in transepithelial potential (TEP) and short-circuit current (Isc).In a dose–response study, 10-fold increases in serosal hydrin 2 concentration triggered significant changes in TEP and Isc, with maximal responses observed at 10 ng/ml. Because hydrin 2 is known to facilitate “cutaneous drinking” in anurans, this study suggests a correlation between ion and water transport across the skin3.
A fluorescent analogue of hydrin 1: a new probe for vasotocin receptors - In a study, deamino and fluorescein analogues of hydrin 1 were used to characterize their physiological action in the urinary bladder of the toad, Bufo marinus. It was shown that 1-Deamino-hydrin 1 (d-hydrin) was more potent than vasotocin in stimulating osmotic water flow across intact bladders and more potent than vasotocin in displacing tritium-labeled vasopressin [(3H] AVP) from cell membranes. Furthermore, 1-Deamino-[11-lysine (fluorescein)]-hydrin 1 (flu-hydrin) was found to be the most potent fluorescent vasotocin receptor probe synthesized to date. Flu-hydrin increased osmotic water flow across bladders with a half-maximal effective dose (ED50) value of 6 x 10(-10) M and displaced [3H]AVP from membranes with a half-maximal concentration (IC50) value of 3 x 10(-9) M. This study shows that d-hydrin can serve as a foundation molecule to which reporter groups, such as fluorescent residues, can be attached with better preservation of hydrosmotic activity than is possible with similar modifications of vasotocin4.
References
1.Rouille Y, Michel G, Chauvet MT, Chauvet J, Acher R (1989). Hydrins, hydroosmotic neurohypophyseal peptides osmoregulatory adaptation in amphibians through vasotocin precursor processing. Proc. Natl. Acad. Sci, 86:5272–5275.
2.Rouille Y, Ouedraogo Y, Chauvet J, Acher R (1995). Distinct hydroosmotic receptors for the neurohypophyseal peptides vasotocin and hydrins in the frog Rana esculenta. Neuropeptides, 29:301–307.
3.Ford NA, Robinson GD (2003). Effects of hydrin 2 on cutaneous electrical properties of Rana pipiens. General and Comparative Endocrinology, 134 (2):103-108.
4.Eggena P, Ma CL, Lu MQ, Buku A (1990). A fluorescent analogue of hydrin 1: a new probe for vasotocin receptors. Am J Physiol Endocrinol Metab, 259:524-528.
Subscribe to:
Posts (Atom)